Neurotrope BioScience

Overview

Overview

Neurotrope BioScience, Inc. (NASDAQ: NTRP) is a clinical-stage biopharmaceutical company headquartered in New York, NY, focused on developing novel therapies for Alzheimer's disease (AD) and other neurodegenerative disorders. The company is known for its development of bryostatin, a protein kinase C (PKC) modulator, as a potential treatment for Alzheimer's disease that aims to promote synaptic repair and neuroprotection["@neurotrope"].

Funding

• IPO: 2017 (NASDAQ: NTRP)

Company Information

| Attribute | Value |
|-----------|-------|
| Founded | 2012 |
| Headquarters | New York, NY, USA |
| Stock Exchange | NASDAQ |
| Ticker | NTRP |
| IPO | 2014 |
| Focus | Alzheimer's disease, neurodegeneration |

History and Milestones

Neurotrope was founded in 2012 with a focus on developing PKC-targeted therapies for neurological disorders. The company went public in 2014 on NASDAQ[@neurotrope].

Key milestones:

• 2012: Company founded
• 2014: Initial public offering (NASDAQ: NTRP)
• 2015: Phase 2 trial initiation for bryostatin in AD
• 2020: Continued clinical development despite challenges
• 2022: Strategic pipeline review and future planning

Technology Platform

Protein Kinase C (PKC) Modulation

Neurotrope's platform centers on protein kinase C (PKC) epsilon (PKCε) activation[@alkon2007]:

• PKC Function: PKC enzymes are critical for synaptic plasticity, memory formation, and neuronal survival
• PKC in AD: PKC signaling is impaired in Alzheimer's disease, contributing to synaptic loss
• Therapeutic Approach: PKC epsilon activation promotes synaptic repair and protects against [amyloid-beta](/proteins/amyloid-beta) toxicity

Bryostatin Chemistry

Bryostatin is a macrocyclic lactone:

• Source: Originally isolated from the marine bryozoan Bugula neritina
• Structure: 26-membered macrolide with multiple lactone rings
• Properties: High molecular weight, complex structure, challenging synthesis

Pipeline

Bryostatin (Bryo 1/2)

| Attribute | Details |
|-----------|---------|
| Indication | Alzheimer's Disease |
| Mechanism | PKC epsilon activator |
| Stage | Phase 2 |
| Route | Intravenous infusion |
| Status | Clinical development |

Potential Benefits:

• Promotes synaptic repair and formation
• Enhances memory and cognitive function
• Reduces amyloid-beta toxicity
• Neuroprotective effects

Preclinical Programs

| Program | Indication | Stage |
|---------|------------|-------|
| PKC modulators | Various CNS disorders | Preclinical |
| Novel analogs | AD, PD | Discovery |

Clinical Development

Phase 2 Trials

Neurotrope has conducted multiple Phase 2 clinical trials evaluating bryostatin in Alzheimer's disease patients[@alkon2007]:

Trial Design:

• Randomized, double-blind, placebo-controlled
• Patients with mild-to-moderate AD
• Primary endpoints: cognitive function (ADAS-Cog), safety
• Secondary endpoints: synaptic biomarkers, functional measures

• Complex intravenous administration
• Dose optimization required
• Variable patient responses

Mechanism in Alzheimer's Disease

Bryostatin's potential benefits in AD include[@alkon2007]:

Scientific Rationale

PKC and Memory

Protein kinase C is essential for memory formation:

• [Long-term Potentiation](/mechanisms/long-term-potentiation) (LTP): PKC activity is required for synaptic strengthening
• Memory Consolidation: PKC signaling during memory encoding
• Synaptic Plasticity: PKC modulates receptor trafficking and ion channel function

Preclinical Evidence

Animal studies show bryostatin:

• Improves performance in memory tasks
• Increases synaptic density in hippocampal regions
• Reduces amyloid plaque burden
• Protects against excitotoxicity

Competitive Landscape

Neurotrope competes in the AD therapeutic space:

| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Biogen/Lecanemab | Amyloid clearance | Antibody | Approved |
| Eli Lilly | [Donanemab](/entities/donanemab) | Amyloid clearance | Approved |
| Roche | Gantenerumab | Amyloid clearance | Phase 3 |
| Neurotrope | Bryostatin | PKC activator | Phase 2 |
| Cortexyme | COR388 | Gingipain inhibitor | Phase 2/3 |

Challenges and Risks

• Administration: IV infusions vs. oral drugs
• Competition: Successful amyloid-targeting therapies
• Efficacy: Demonstrating clinical benefit
• Manufacturing: Complex bryostatin synthesis
• [Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
• [Protein Kinase C Signaling](/mechanisms/protein-kinase-c-signaling)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Amyloid-Beta Hypothesis](/genes/th)

External Links

• [Neurotrope BioScience Website](https://www.neurotrope.com)
• [ClinicalTrials.gov - Neurotrope](https://clinicaltrials.gov/search?spons=Neurotrope)
• [PubMed - Bryostatin Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=bryostatin+Alzheimer)

References